NewEdge Wealth’s Anixa Biosciences ANIX Stock Holding History

NewEdge Wealth’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.3K	Hold	12,500	–	–	﹤0.01%	1118
2025 Q4	$39K	Hold	12,500	–	–	﹤0.01%	1184
2025 Q3	$50.9K	Hold	12,500	–	–	﹤0.01%	1013
2025 Q2	$37.6K	Buy	+12,500	New	+$35.7K	﹤0.01%	958

Other funds holding ANIX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NewEdge Wealth's ANIX Position: Q1 2026 in Review

NewEdge Wealth held its Anixa Biosciences (ANIX) position steady in Q1 2026 at 12,500 shares worth $32.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1118.

NewEdge Wealth first reported a position in ANIX in Q2 2025 and has held it in 4 quarters since. The position peaked at $50.9K in Q3 2025. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

NewEdge Wealth held 12,500 shares of Anixa Biosciences worth $32.3K as of Q1 2026.
NewEdge Wealth left its Anixa Biosciences share count unchanged in Q1 2026.
Anixa Biosciences made up ﹤0.01% of NewEdge Wealth's portfolio in Q1 2026, its #1118 holding.
NewEdge Wealth first reported a position in Anixa Biosciences in Q2 2025 and has held it in 4 quarters since.
NewEdge Wealth's Anixa Biosciences position peaked at $50.9K in Q3 2025.
60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on NewEdge Wealth's 13F filing for Q1 2026, filed 13 May 2026.